Thrombotic Complications Associated with Immune Checkpoint Inhibitors

Tzu-Fei Wang 1,* Alok A. Khorana 2 and Marc Carrier 1

1 Department of Medicine, University of Ottawa, The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; mcarrier@toh.ca
2 Taussig Cancer Institute, Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, OH 44106, USA; khorana@ccf.org
* Correspondence: tzwang@toh.ca

Simple Summary: Patients with cancer commonly develop blood clots, which can cause issues including hospitalizations and complications and can affect cancer treatments. Cancer therapies can be one of the reasons for blood clots. A type of cancer therapy called “immune checkpoint inhibitors” has been used more and more often in recent years for different types of cancer. Recent reports revealed an increasing concern of blood clots related to immune checkpoint inhibitors. In this review, we will summarize data from the available studies and discuss the rates, risk factors, prevention, and treatment strategies for blood clots related to immune checkpoint inhibitors.

Abstract: Thromboembolism is a common complication in patients with cancer and is associated with significant morbidity and mortality. Anticancer treatment is a known risk factor of cancer-associated thrombosis. Immune checkpoint inhibitors have become a mainstay of treatment in various cancers. Both venous and arterial thrombosis have been increasingly reported as adverse events associated with immune checkpoint inhibitors in recent studies, with a cumulative incidence of venous thrombosis to be 5–8% at 6 months and over 10% at 12 months. Additionally, rates of approximately 1–5% for arterial thrombosis were reported at 12 months. Data also showed an association of thromboembolism with adverse survival. Many pertinent clinical questions in this population deserve further investigation, including the risks of thrombosis associated with immune checkpoint inhibitors as compared to those with traditional systemic therapy, associated risk factors, and the optimal prevention and treatment strategies. In this review, we synthesize data from available literature, provide relevant information for clinicians and potential future directions for research.

Keywords: venous thromboembolism; arterial thrombosis; cancer-associated thrombosis; immune checkpoint inhibitors; anticoagulation

1. Introduction

Patients with cancer have a 12-fold increased risk of venous thromboembolism (VTE) compared to the general population, with the risk further increased to 23-fold in patients receiving chemotherapy or targeted therapy [1]. Cancer-associated thrombosis is linked with significant morbidity that could lead to hospitalizations, delay in cancer treatment, and even mortality. As a result, thromboembolism is the second leading cause of death in cancer patients [2]. Many factors can contribute to the increased risk of thrombosis in patients with cancer, including tumor-related factors such as type and stage of malignancy; patient-related factors such as age, history of VTE, obesity, or other co-morbidities; and treatment-related factors such as surgery or systemic anticancer therapies [3].

In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the landscape of oncology treatment. ICIs are monoclonal antibodies that target proteins that negatively regulate the immune system called immune checkpoints, including programmed cell death (PD)-1 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) [4]. PD-1 and
CTLA-4 are typically expressed on T cells and bind to PD-1 ligands on tumor cells and CD80/CD86 on antigen-presenting cells, respectively. This leads to T cell inactivation to keep the immune response in check [4]. However, tumor cells also commonly utilize this pathway to escape the immune system. Blocking these pathways results in the activation of T cells to target and kill tumor cells [4]. The United States Food and Drug Administration (FDA) approved the first ICI in 2011; by 2020, seven ICIs had been approved by the FDA in at least 15 cancers, and patients eligible for ICIs significantly increased from 1.5% in 2011 to 43.6% in 2018 [5,6]. They have become a mainstay of treatment and are widely used in various cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, head and neck cancer, and more. Available ICIs target PD-1 (nivolumab, pembrolizumab, cemiplimab) or its ligands (atezolizumab, avelumab, durvalumab) as well as CTLA-4 (ipilimumab). ICIs are known to be associated with a wide range of immune-related toxicities, including gastrointestinal, skin, thyroid, or hematological findings such as autoimmune hemolytic anemia or thrombocytopenia.

Thrombosis had not been a commonly reported adverse event in initial phase III clinical trials leading to the approval of ICIs. However, after the routine clinical use of these agents, multiple studies started to report concerns for thrombosis, although rates varied widely. Data were also conflicting on whether ICIs were indeed associated with a higher risk of thrombosis than traditional chemotherapy.

Therefore, we review the current literature on venous or arterial thrombosis associated with ICIs. We will address potential mechanisms of thrombosis, summarize the reported rates of venous and arterial thrombosis among various studies, discuss treatment and prevention of thrombotic complications and risk factors for thrombosis in patients receiving ICIs.

2. Methods

For this review, we performed a comprehensive literature search of the MEDLINE database from inception to 11 July 2021. Search terms included (“thromboembolism” OR “thrombosis”) AND (“cancer” OR “malignancy”) AND (“immune checkpoint inhibitor” OR “immunotherapy”). All prospective or retrospective cohort studies, meta-analyses, and review articles pertinent to the topic were reviewed. After excluding duplicates, 690 articles were screened by titles and abstracts. The references in the relevant articles were also manually searched for related studies. Overall, 18 retrospective studies reporting incidences and/or outcomes of venous and/or arterial thrombosis in patients on ICIs [1,7–23] and 4 additional relevant systematic reviews and meta-analyses [24–27] were identified and included in this review.

3. Mechanism of Thrombosis Related to Immune Checkpoint Inhibitors

While the exact mechanisms of thrombosis associated with ICIs remain to be elucidated, several pathways have been considered. Immune checkpoint blockage has been demonstrated to be associated with a pro-inflammatory state and elevated levels of inflammatory cytokines [28]. Furthermore, mouse models showed that PD-1 played a crucial role in downregulating pro-atherogenic T cells, and blockage of PD-1 could accelerate atherogenesis with increased infiltration of macrophages and pro-inflammatory T cells in atherosclerotic plaques and enhance vascular inflammation and atherosclerosis [29,30]. The promotion of atherosclerotic plaques after ICI use was demonstrated in pre-clinical animal models and could potentially contribute to the increased arterial thrombotic events [31].

In addition, activated T cells can induce synthesis of tissue factor in monocytes and macrophages [32] and is hypothesized to be one of the mechanisms that promote hypercoagulability [33]. To further delineate the pathogenesis of ICI-associated VTE, Roopkumar et al. analyzed pre-ICI blood samples from 15 individuals who subsequently developed VTE on ICIs compared to 10 without VTE on ICIs [21]. In patients who developed a VTE, they found a significant increase in the numbers of total myeloid-derived suppressor cells (MDSCs) and elevated levels of inflammatory biomarkers, including CXCL8 (chemokine
ligand), soluble vascular cell adhesion molecule 1, and clustering of other inflammatory cytokines including IL-1β, IL-6, TNF prior to ICI. The potential link between MDSCs and thrombosis is intriguing and could be related to platelet activation triggered by MDSCs, as found in an in-vitro study when MDSCs were exposed to metastatic tumor cells [34], as well as in other thromboinflammatory disorders such as the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-1) infection [35]. MDSCs can also release neutrophil extracellular traps (NETs) induced by CXCL8-involved pathways and contribute to a heightened risk of thrombosis [21,36]. Moreover, the elevation of other cytokines is hypothesized to cause activation of endothelium and platelets and activate the pathologic process of immunothrombosis [21,37]. These inflammatory biomarkers could potentially be used to identify patients at high risk for VTE on ICIs in the future.

4. Incidence of Thrombosis

4.1. Venous Thromboembolism (VTE)

A systematic review and meta-analysis including 68 studies (18 retrospective studies with the rest being clinical trials investigating the efficacy of ICIs, N = 20,273) showed an incidence of VTE and ATE of 2.7% (95% CI 1.4–5.4%) and 1.1% (95% CI 0.65–1.45%) in cancer patients receiving ICIs, respectively [26]. The authors concluded that ICIs were associated with low incidences of thromboembolic events, not different from chemotherapy alone. However, this systematic review was limited in that the definition of thromboembolic events and the follow-up duration in each study varied and were often unclear. In addition, 40% of the eligible studies did not report on thromboembolic events and were excluded from the analysis [38]. In contrast to the low rates reported from initial clinical trials, more recent studies revealed a much higher rate of thrombosis.

Tables 1 and 2 summarize the characteristics and reported outcomes in studies focusing on VTE and/or ATE in patients receiving ICIs. A total of 18 studies were included; all were retrospective, including two population cohorts. There was a male predominance, with the majority of patients having metastatic disease (80–100%). The most common cancer types included lung, renal cell, and melanoma (Table 1). The follow-up duration varied widely, ranging from 6 to 37.8 months, and accordingly, the incidence of thrombosis also varied, and it was difficult to conclude a definitive rate. In general, the cumulative incidence of VTE is approximately 5–8% at 6 months and over 10% at 12 months (Table 2). These rates are much higher than the reported rate of 2.7% from the previous meta-analysis. These findings suggest concerning evidence that thromboembolic events are commonly under-reported or under-estimated in oncology clinical trials where the primary goal is to evaluate the effectiveness of anticancer therapies, and thromboembolism is often reported as adverse events (not primary or secondary outcomes) by using Common Terminology Criteria for Adverse Events (CTCAE). The under-reporting of thromboembolic complications has also been reported in colorectal and pancreatic cancer trials [39,40]. As such, the subcommittee on Haemostasis and Malignancy of the International Society on Thrombosis and Haemostasis (ISTH) has called for standardization of reporting and analysis of VTE events in patients with cancer [41]. This is important as inconsistent reporting could lead to erroneous estimates of true event rates and missing potentially important adverse events.
Table 1. Baseline characteristics of studies including patients on immune checkpoint inhibitors.

| Study                          | Study Design                     | N     | Age (Median, IQR)       | Male, % (n) | Stage IV, % (n) | Type of Cancer                  |
|-------------------------------|----------------------------------|-------|-------------------------|-------------|----------------|---------------------------------|
| Hegde et al. 2017 [7] abstract | Retrospective                    | 76    | N/A                     | N/A         | N/A            | Lung                            |
| Ibrahimi et al. 2017 [8] abstract | Retrospective                    | 154   | 63 (range 23–89)        | 43% (66)    | 92% (142)      | Lung 20.8% Melanoma 20.1% Ovarian 12.3% |
| Hou et al. 2018 [9]           | Retrospective                    | 50    | 58.7 (mean, range 37–80)| 58% (29)    | 74% (37)       | All cancers NSCLC 48%           |
| Bar et al. 2019 [10]          | Retrospective                    | 1215  | 52.3% ≥ 65              | 59% (717)   | N/A            | All cancers Melanoma 40.5% Lung 28.7% |
| Nichetti et al. 2019 [11]     | Retrospective analysis from prospective APOLLO cohort | 217   | 70 (range 32–90)        | 62.7% (136) | 95.4% (207)    | NSCLC                           |
| Ando et al. 2020 [12]         | Retrospective                    | 122   | N/A                     | 74.6% (91)  | N/A            | Lung, kidney, stomach, urothelial, melanoma |
| Drobni et al. 2020 [13]       | Retrospective (case control and case cross-over) | 2842  | 66 (57–74)              | 57.4% (1631)| N/A            | All cancer NSCLC 28.8% Melanoma 27.9% |
| Deschênes-Simard et al. 2021 [14] | Retrospective                    | 593   | 66.7 (60.4–72.5)        | 54.3% (322) | 87.2% (368)    | NSCLC                           |
| Gutierrez-Sainz et al. 2021 [15] | Retrospective                    | 229   | 64 (range 19–86)        | 63.8% (146) | 96.5% (221)    | Lung 48% Melanoma 23.6% RCC 11.8% |
| Guven et al. 2021 [16]        | Retrospective                    | 133   | 60 (48–66)              | 64.7% (86)  | 100% (133)     | Renal cell 26.3% Melanoma 24.1%, NSCLC |
| Icht et al. 2021 [17]         | Retrospective                    | 176   | 66 (60–72)              | 60.8% (107) | 85.8% (151)    | NSCLC                           |
| Kewan et al. 2021 [18]        | Retrospective                    | 552   | 38.8 (range 26.8–94.8)  | 65% (359)   | 100% (552)     | All cancers NSCLC 47.3%         |
| Madison et al. 2021 [19]      | Retrospective                    | 6127 *| 69–71 * (range 30–96)   | 97.4% (5967)| N/A            | Lung                            |
| Moik et al. 2021 [20]         | Retrospective                    | 672   | 64 (54–72)              | 61.3% (412) | 85.8% (566)    | Melanoma 30.4% NSCLC 24.1% RCC 11% |
| Mulder et al. 2021 [1]        | Population cohort                | 370   | N/A                     | N/A         | N/A            | All cancers                     |
| Roopkumar et al. 2021 [21]    | Retrospective                    | 1686  | Mean 64.5 (range 18–93) | 60.1% (1014)| 90.3% (1523)   | Lung 49.6% Melanoma 13.2%       |
| Sussman et al. 2021 [22]      | Retrospective                    | 228   | 65.5 (range 23–91)      | 67.5% (154) | 81.1% (181)    | Melanoma                        |
| Moik et al. 2021 [23] abstract | Population cohort                | 3259  | N/A                     | N/A         | N/A            | All cancers                     |

* including N = 2678 for immune checkpoint inhibitors alone, and N = 3449 for immune checkpoint inhibitors plus chemotherapy, median age reported by groups (immune checkpoint inhibitors alone or immune checkpoint inhibitors plus chemotherapy). Abbreviations: N—number of patients included; SCLC—non-small cell lung cancer; N/A—not available; RCC—renal cell carcinoma.
Table 2. Thrombotic outcomes and risk factors in patients on immune checkpoint inhibitors in included studies.

| Study                        | Study Design | N     | Follow Up [Median (IQR, Unless Specified)] | VTE Incidence (% 95% CI) | ATE Incidence (% 95% CI) | Risk Factors for Thrombosis | Comments                                      |
|------------------------------|--------------|-------|--------------------------------------------|--------------------------|--------------------------|-----------------------------|---------------------------------------------|
| Hegde et al. 2017 [7]        | Retrospective | 76    | 10.8 mo                                    | 18.4                     | 2.6                      | Female                      | VTE after ICI did not affect survival, but before ICI did |
| Ibrahimi et al. 2017 [8]     | Abstract     | 154   | 7 mo (198 days)                            | 10.4                     | 0                        | N/A                         | VTE was not associated with progression-free survival |
| Hsu et al. 2018 [9]          | Retrospective | 50    | N/A                                        | 2                        | N/A                      | N/A                         | Focused on survival and toxicity No follow up duration nor how VTE assessed |
| Bar et al. 2019 [10]         | Retrospective | 1215  | 12 mo                                      | AVE (including MI, stroke, PE, multisite DVT): 6 mo: 2.6 12 mo: 3.0 AVE plus single site DVT: 6 mo: 4.9 12 mo: 5.8 | • NSCLC • History of AVE • Hypertension • Dyslipidemia | AVE was associated with worse survival Rate of AVE was similar in ICI vs. chemo vs. ICI+chemo in lung cancer |
| Nichetti et al. 2019 [11]    | Retrospective analysis from prospective APOLLO cohort | 217  | 37.8 mo                                   | 7.4                      | 6.5                      | Current smoker • PD-L1 > 50% • Not: • KS • Anticoagulant or antiplatelet agents | TE is associated with worse survival after TE |
| Ando et al. 2020 [12]        | Retrospective | 122   | Time to thrombosis 90 days (range 6–178) | 4.3                      | 4.9                      | History of TE               | No follow up duration, unclear definition of TE |
| Drobni et al. 2020 [13]      | Retrospective | 2842  | 2 years                                   | N/A                      | Composite: 5.35/100 person-yrs MI: 2.49 Stroke: 2.08 | Overall study: ICIs, age, h/o stroke, diabetes, hypertension, NSCLC, male, history of radiation | ICI was associated with increased risk of composite cardiovascular events Statin and steroids attenuated atherosclerotic plaque progression |
| Deschénes-Simard et al. 2021 [14] | Retrospective | 593  | 12.7 (4.9–22.7) mo                        | 9.9 (7.5–12.3) 76.5 (59.9–97.8) per 1000 person-years | 1.3                      | Age < 65 • Higher PD-L1 level • Smoking • <12 mo from diagnosis to ICIs | VTE was not correlated with survival |
| Gutierrez-Sainz et al. 2021 [15] | Retrospective | 229  | 9.8 mo                                    | 7 (4–10)                 | N/A                      | Female • Melanoma           | VTE was not an independent factor for shorter survival |
| Guven et al. 2021 [16]       | Retrospective | 133   | 10.1 (5.8–18.5) mo                        | 11.3                     | N/A                      | ECOG ≥ 1 Not: • KS          | Median survival numerically shorter in VTE patients, not significant |
Table 2. Cont.

| Study                          | Study Design    | N     | Follow Up [Median (IQR), Unless Specified] | VTE Incidence (%; 95% CI) | ATE Incidence (%; 95% CI) | Risk Factors for Thrombosis                                                                 | Comments |
|--------------------------------|-----------------|-------|--------------------------------------------|---------------------------|---------------------------|---------------------------------------------------------------------------------------------|----------|
| Icht et al. 2021 [17]          | Retrospective   | 176   | 6 mo (187 days)                             | 4.5 (2.1–8.3)             | N/A                       | Not: KS VTE was associated with death                                                       |          |
| Kewan et al. 2021 [18]         | Retrospective   | 552   | 12.1 mo                                    | 12.1                      | 1.3                       | • AC use at the time of ICIs (univariable) Not: KS Median time to VTE 3.8 mo KS predicts overall survival |          |
| Madison et al. 2021 [19]       | Retrospective   | 6143 *| 6 mo                                       | 6.3                       | 2.6                       | N/A ICIs were associated with higher risk of thrombosis compared to chemo alone but not significant in multivariable analysis |          |
| Moik et al. 2021 [20]          | Retrospective   | 672   | 8.5 mo                                     | 6 mo: 5.0 (3.4–6.9) Overall: 12.9 (8.2–18.5) | 6 mo: 1.0 (0.4–2.0) Overall 1.8 (0.7–3.6) | • History of VTE Not: • KS VTE (after ICI) was associated with worse survival |          |
| Mulder et al. 2021 [1]         | Population cohort | 370   | 12 mo                                      | 6 mo: 4.1 (2.3–6.7) 12 mo: 7.1 (4.2–11.1) | N/A                       | N/A N/A VTE was associated with worse survival |          |
| Roopkumar et al. 2021 [21]     | Retrospective   | 1686  | 438 days (range 7–1971)                    | 6 mo: 7.1 12 mo: 10.9 Overall: 24 | N/A                       | • Younger age • Metastasis • Biomarkers VTE was associated with worse survival No difference in VTE incidence with types of ICIs |          |
| Sussman et al. 2021 [22]       | Retrospective   | 228   | 27.3 mo                                    | 6 mo: 8.0 (4.9–12.0) 12 mo: 12.9 (8.9–17.7) | 6 mo: 2.2 (0.84–4.8) 12 mo: 4.5 (2.3–7.8) | • Combination ICI KS ≥ 1 • History of CAD • Anticoagulation at treatment start VTE was associated with worse survival |          |
| Moik et al. 2021 [23]          | Population cohort | 3259  | 24 mo                                      | 6 mo: 3.9 (3.3–4.7) 12 mo: 5.7 (4.9–6.6) 24 mo: 7.5 (6.2–8.4) | 6 mo: 1.3 (0.9–1.8) 12 mo: 2.2 (1.7–2.8) 24 mo: 3.1 (2.4–3.8) | N/A Use of ICI was associated with 1.5 to 6.5 fold increased odds of VTE |          |

* including N = 2685 for ICIs alone, and N = 3458 for ICIs plus chemotherapy, median age reported by groups (ICIs alone or ICIs plus chemotherapy). Abbreviations: ATE—arterial thrombosis; AVE—acute vascular events; CAD—coronary artery disease; DVT—deep vein thrombosis; ECOG—Eastern Cooperative Oncology Group; h/o—history of; ICIs—immune checkpoint inhibitors; IQR—interquartile range; KS—Khorana score; MI—myocardial infarction; mo—months; N—number of patients included; N/A—not available; NSCLC—non-small cell lung cancer; PE—pulmonary embolism; TE—thromboembolism; VTE—venous thromboembolism.
Additionally, whether ICIs are associated with an increased risk of VTE compared to traditional chemotherapy is unclear, as patients receiving ICIs and chemotherapy are usually not directly comparable, and many studies only included patients on ICIs or ICI combinations. Four studies have attempted to compare rates of thrombotic complications in patients receiving ICIs to those receiving chemotherapy. Bar et al. did not find a difference in thrombotic complications in patients on ICIs, chemotherapy alone, or a combination of ICIs and chemotherapy [10]. Similarly, a Danish population cohort study showed a 6-month cumulative incidence of VTE of 4.1% (95% CI 2.3–6.7%) in patients receiving ICIs, comparable to 3.5% (95% CI 3.4–3.6%) found in those receiving chemotherapy [1]. In another study, Icht et al. included 345 patients with NSCLC and reported a 6-month cumulative incidence of VTE of 7.1% in the chemotherapy cohort, compared with 4.5% in the ICI cohort (HR 1.6, 95% CI 0.6–3.9) [17]. However, as expected, the two cohorts were significantly different in baseline characteristics, including more metastatic disease and much less use as first-line therapy in the ICI cohort, which could have affected the results. Lastly, Madison et al. showed that ICIs were associated with a higher risk of thrombosis compared to chemotherapy alone (10.2% vs. 7.6%, respectively) in the univariable analysis, but multivariable analysis failed to show ICI as an independent risk factor for VTE [19], indicating the presence of other confounders. In a report from the FDA Adverse Event Reporting System (FAERS), 1855 patients with ICI-associated thromboembolic events were reported between 2004 and 2019 [42]. Compared to the whole database (which included chemotherapy and protein kinase inhibitors), ICIs were associated with an increased risk of VTE and ATE (reporting odds ratio 2.81 and 1.44, respectively) [42]. However, reporting was voluntary, so biased reporting was highly likely. Therefore, the available data so far did not show a clear differentiation in the rates of thromboembolic events associated with ICIs compared to chemotherapy, although the quality of data remains poor.

Another important consideration is the prolonged use of ICIs and that the occurrence of thrombosis could spread throughout the duration of use. A recent Danish population-based cohort study of 499,092 patients with first cancer diagnosis between 1997 and 2017 showed that in 370 patients treated with ICIs, a 6-month cumulative incidence of VTE following cancer diagnosis was 4.1% (95% CI 2.3–6.7%), with a 12-month cumulative incidence of 7.1% (95% CI 4.2–11.1%) [1]. This indicated that the heightened risks associated with ICIs continued beyond the initial 6 months. Another analysis of the prospective APOLLO cohort in patients receiving ICIs for NSCLC also showed that two-thirds of the VTE occurred after 6 months [11]. This is in contrast with chemotherapy-related VTE, for which the majority of events occur within the first 6 months of initiating therapy [43]. Furthermore, given their improved effectiveness, patients receiving ICIs have prolonged survival with ongoing treatment, which increases the duration of exposure to ICIs and associated risk for thrombosis. Indeed, APOLLO cohort analysis showed that patients with either venous or arterial thromboembolism had significantly longer treatment durations, receiving a median of 20 cycles compared to 6 in those without thrombotic events [11].

Overall, more recent studies have revealed concerns that the risks of ICI-associated VTE were not as low as previously reported in clinical trials focusing on the efficacy of ICIs. However, the actual incidence rates remain to be elucidated. For future trials in cancer patients, it is crucial to standardize reporting of VTE to be objectively confirmed and include important characteristics of VTE events (such as distal vs. proximal, incidental vs. symptomatic, deep vein thrombosis vs. pulmonary embolism, etc.) as well as the standardized duration of follow-up [41].

### 4.2. Arterial Thrombosis

As noted previously, pre-clinical studies have shown that blockage of PD-1 or CTLA-4 could enhance atherosclerotic inflammation and promote atherosclerosis plaques [29,30]. Four meta-analyses (mostly of clinical trials) have shown a rate of myocardial infarction of ≤ 1% and that of stroke of 1–2% (Table 3), but as with VTE, the rates could be under-
Fewer retrospective studies have reported variable rates of ATE, ranging from 1 to 5% at 12 months (Table 2).

Table 3. Meta-analyses reporting thrombotic outcomes in patients on immune checkpoint inhibitors.

| Study               | Search Cut-Off Date | N          | Cancer Types | Rate of VTE, % (95% CI) | Rate of ATE, % (95% CI) |
|---------------------|---------------------|------------|--------------|-------------------------|-------------------------|
| Hu et al. [24]      | 24 March 2017       | 4828 (22 studies) | NSCLC Only one PE reported | MI (n = 402): 1.0 (0.3–3.8) Stroke (n = 135): 2.0 (0–13.0) |
| Nso et al. [25]     | 15 May 2020         | 4622 (26 studies) | Various N/A | MI (n = 1168): 0.4 (CI 0.1–0.7) |
| Solina et al. [26]  | 21 May 2020         | 20,273 (68 studies) | Various | Overall: 2.7 (1.8–4) PE: 1.6 (0.7–3.2) DVT: 2.7 (1.4–5.4) Overall: 1.1 (0.5–2.1) MI: 0.7 (0.15–1.15) Stroke: 1.1 (0.65–1.45) |
| Agostinneto et al. [27] | 30 June 2020       | 35,337 (80 RCTs) | Various N/A | ICI group: MI: 0.41% (27/6607) Dual ICI: MI: 0.5% (1/202) |

Abbreviations: ATE—arterial thrombosis; CI—confidence interval; DVT—deep vein thrombosis; ICI—immune checkpoint inhibitors; MI—myocardial infarction; N—number of patients included; N/A—not available; NSCLC—non-small cell lung cancer; PE—pulmonary embolism; RCTs—randomized controlled trials; VTE—venous thromboembolism.

Drobni et al. showed that ICIs were associated with an increased risk of arterial thrombosis compared to other anticancer therapy [13]. Findings were similar when patients were used as their own control to compare the risks of arterial thrombosis before and after receiving ICIs [13]. Interestingly, this was also the only study investigating the use of steroids or statins, commonly used to modulate autoimmune dysfunction or to modify cardiovascular risk factors, respectively, and found benefits with both to attenuate atherosclerotic plaque progression in patients receiving ICIs [13]. Optimization and control of cardiovascular risk factors may provide benefits in this population, which requires further investigation.

5. Treatment of Thrombosis

Treatment of VTE in patients with cancer on ICIs is not different from other cancer-associated thromboses, which has been covered extensively by recent guidelines and review articles [44–46]. Direct oral anticoagulants (DOACs) and low-molecular-weight-heparin are currently the main treatment options for cancer-associated thrombosis. Choice of anticoagulants would depend on tumor types (with the associated risk of bleeding complications), additional risk factors (such as thrombocytopenia, the presence of intracranial tumors, etc.), potential drug-drug interactions (DDI), and patient perspectives [44]. Fortunately, since ICIs are monoclonal antibodies, no significant DDIs with anticoagulants are expected or reported to date. However, ICIs may be used concurrently with other anticancer therapies or supportive care medications, which could still have potential DDIs, and therefore evaluation of DDIs among all concomitant medications remains advisable.

The optimal treatment of arterial thrombosis in patients with cancer is less clear as data are even scarcer. Standard-of-care similar to what is provided for the non-cancer population is typically employed, including the utilization of antiplatelet agents with or without anticoagulation, modification of cardiovascular risk factors such as control of blood pressure, diabetes, smoking cessation, etc., and/or revascularization when indicated.

6. Prevention of Thrombosis

Two recent large RCTs established the role of DOACs as primary thromboprophylaxis in ambulatory cancer patients with a Khorana score ≥ 2 [47,48]. The Khorana score was derived in a patient population starting a new line of chemotherapy, and whether it can be applied to patients on ICIs is not fully understood. Most studies that investigated the Khorana score for its prediction performance in patients receiving ICIs have not found it to be predictive [11,16–18,20]. This indicates that patients on ICIs likely have different sets of risk factors compared to those on chemotherapy, and a specific risk assessment model in this population may be needed.

Many studies have attempted to identify risk factors for thromboembolic events in this population (Table 2). However, most studies were small and single-center, and therefore,
not surprisingly, different sets of risk factors were identified from each study, including a history of thromboembolic disease, metastasis, poor performance status, lung cancer, or melanoma, and more (Table 2). It is worth noting that many of these studies tended to perform multivariable analyses with many variables from datasets with a limited number of patients and associated outcome events, leading to potential model overfit that could make results questionable [10,12,15,16,18]. Future research is needed to derive and validate a specific risk assessment model in a larger patient population receiving ICIs, which can help risk prediction and tailor thromboprophylaxis, if needed, in this growing population.

For primary prevention of arterial events, standard-of-care as in non-cancer population can be of benefit, including careful assessment of cardiovascular risk factors, such as smoking, obesity, hypertension, hyperlipidemia, diabetes, etc., and aggressive modification of these risk factors with lifestyle change or medications such as statins. As noted previously in the study from Drobni et al., steroids or statins may modify atherosclerotic plaques while on ICIs, but more research is needed [13]. In addition, aspirin or statin use at the time of ICI initiation was shown to be associated with an increased response rate to ICIs in a multicenter retrospective study of 1012 patients. This finding is interesting and hypothesis-generating for future investigation [49].

7. Survival and Thrombosis in Patients Receiving Immune Checkpoint Inhibitors

In patients receiving ICIs, several studies have shown that the occurrence of thrombosis was associated with worsening survival [10,11,20–22] while others have not [14–16] (Table 2). Possible explanations of worse survival in patients who developed VTE include that thrombosis is an indicator for more advanced cancer stage, worse prognosis, poorer performance status, and/or thrombosis or anticoagulation-related mortality.

Pre-clinical studies have demonstrated that coagulation factors such as factor X can help tumors escape the immune system [50]. Factor X inhibitors such as rivaroxaban were shown to enhance the effects of ICIs and immunity against tumor cells and inhibit tumor growth in mice models [50,51]. It is of great interest whether this finding can be translated into a clinical setting. However, a recent retrospective study showed no difference in response rates, progression-free or overall survival in patients receiving ICIs and therapeutic anticoagulation compared to patients who were not on anticoagulation [52]. Of note, anticoagulation included in this study was not limited to factor X inhibitors (including dabigatran, rivaroxaban, apixaban, enoxaparin, and warfarin). Moreover, the cohort of patients on anticoagulation in the study was significantly older, with poorer performance status, and a higher percentage had lung cancer, all of which were poor prognostic factors [52]. The authors performed a multivariable analysis to adjust for confounders and reached the same conclusions, but residual confounding could be present. More studies with larger sample sizes are needed.

8. Conclusions

ICIs have become the main treatment strategy in cancer and result in prolonged survival. Recent observational studies have shown concerns for increased risks of both venous and arterial thromboses in patients receiving ICIs than previously perceived, and patients with thromboembolic complications while on ICIs had also been shown to have worsened survival in some studies, but whether the risks are higher compared to those associated with chemotherapy remain unclear. It is important for clinicians to be aware of the potential thrombotic complications, to educate patients and recognize signs and symptoms of thrombosis, to allow prompt treatment if needed and avoid complications. Future research to evaluate risk factors and develop robust risk assessment models to allow risk stratification and effective utilization of thromboprophylaxis in this population is needed. Furthermore, whether the concurrent use of anti-Xa inhibitors, aspirin, or statins can enhance the effects of ICIs and lead to better antitumor effects and survival is of great interest.
Author Contributions: Conceptualization: T.-F.W.; Data interpretation: T.-F.W., A.A.K. and M.C.; Original draft preparation: T.-F.W.; Review and editing: T.-F.W., A.A.K. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: A.A.K. gratefully acknowledges research support from the Sondra and Stephen Hardis Chair in Oncology Research and the National Heart, Lung and Blood Institute (Consortium Linking Oncology with Thrombosis, CLOT-U01HL143402). M.C. is the recipient of Tier 1 Research Chair from the University of Ottawa in Cancer and Thrombosis.

Conflicts of Interest: T.-F.W. reports advisory board honoraria from Servier and grants from Leo Pharma. A.A.K. reports personal fees and non-financial support from Janssen, Bayer, Anthos, Pfizer, Seattle Genetics, Sanofi; personal fees and non-financial support from Medscape/WebMD; research grants to his institution from Merck, Array, Bristol-Myers Squibb, Leap Pharma. M. Carrier reports grants from BMS, Leo Pharma, and Pfizer, personal fees from BMS, Leo Pharma, Bayer, Pfizer, Servier, and Sanofi.

References

1. Mulder, F.I.; Horvath-Puho, E.; van Es, N.; van Laarhoven, H.W.M.; Pedersen, L.; Moik, F.; Ay, C.; Buller, H.R.; Sorensen, H.T. Venous thromboembolism in cancer patients: A population-based cohort study. Blood 2021, 137, 1959–1969. [CrossRef] [PubMed]

2. Khorana, A.A.; Francis, C.W.; Culakova, E.; Kuderer, N.M.; Lyman, G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 2007, 5, 632–634. [CrossRef] [PubMed]

3. Ay, C.; Pabinger, I.; Cohen, A.T. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb. Haemost. 2017, 117, 219–230. [CrossRef] [PubMed]

4. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56–61. [CrossRef] [PubMed]

5. Haslam, A.; Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2019, 2, e192535. [CrossRef]

6. Vaddepally, R.K.; Kharel, P.; Pandey, R.; Garje, R.; Chandra, A.B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 2020, 12, 738. [CrossRef]

7. Hegde, A.M.; Stroud, C.R.; Cherry, C.R.; Yogarajah, M.; Cherukuri, S.D.; Walker, P.R. Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab. J. Clin. Oncol. 2017, 35, e20624. [CrossRef]

8. Ibrahimi, S.; Machiorlatti, M.; Vesely, S.K.; Malla, M.; Modhia, F.; Jones, S.A.; Roman, D.; Cherry, M.A. Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience; American Society of Hematology: Washington, DC, USA, 2017; p. 4864.

9. Hsu, J.C.; Lin, J.Y.; Hsu, M.Y.; Lin, P.C. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. PLoS ONE 2018, 13, e0202725. [CrossRef] [PubMed]

10. Bar, J.; Markel, G.; Gottfried, T.; Percik, R.; Leibowitz-Amit, R.; Berger, R.; Golan, T.; Daheer, S.; Taliansky, A.; Dudnik, E.; et al. Acute vascular events as a possibly related adverse event of immunotherapy: A single-institute retrospective study. Eur. J. Cancer 2019, 120, 122–131. [CrossRef]

11. Nichetti, F.; Ligorio, F.; Zattarin, E.; Signorelli, D.; Prelad, A.; Proto, C.; Galli, G.; Marra, A.; Apollonio, G.; Porcu, L.; et al. Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers 2019, 12, 67. [CrossRef]

12. Ando, Y.; Hayashi, T.; Sugimoto, R.; Nishibe, S.; Ito, K.; Kawada, K.; Ikeda, Y.; Yamada, S.; Imaizumi, K. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest. New Drugs 2020, 38, 1200–1206. [CrossRef]

13. Drobn, Z.D.; Alvi, R.M.; Taron, J.; Zafar, A.; Murphy, S.P.; Rambarat, P.K.; Mosarla, R.C.; Lee, C.; Zlotoff, D.A.; Raghu, V.K.; et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020, 142, 2299–2311. [CrossRef]

14. Deschenes-Simard, X.; Richard, C.; Galland, L.; Blais, F.; Desilets, A.; Malo, J.; Cvetkovic, L.; Belkaid, W.; Elkrief, A.; Gagne, A.; et al. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thromb. Res. 2021, 205, 29–39. [CrossRef] [PubMed]

15. Gutierrez-Sainz, L.; Martinez-Marin, V.; Vinal, D.; Martinez-Perez, D.; Pedregosa, J.; Garcia-Cuesta, J.A.; Villamayor, J.; Zamora, P.; Pinto, A.; Redondo, A.; et al. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: A single-institution experience. Clin. Transl. Oncol. 2021, 23, 1245–1252. [CrossRef] [PubMed]

16. Guven, D.C.; Aksun, M.S.; Sahin, T.K.; Aktepe, O.H.; Yildirim, H.C.; Taban, H.; Ceylan, F.; Kertmen, N.; Arik, Z.; Dizdar, O.; et al. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Supportive Care Cancer 2021, 29, 5417–5423. [CrossRef] [PubMed]
17. Ichti, O.; Darzi, N.; Shimony, S.; Jacob, O.; Reinhorn, D.; Landman, Y.; Mutai, R.; Averbuch, I.; Shochat, T.; Spectre, G.; et al. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J. Thromb. Haemost. 2021, 19, 1250–1258. [CrossRef]

18. Kewan, T.; Ko, T.; Flores, M.; Sallam, Y.; Haddad, A.; Daw, H. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors. Eur. J. Haematol. 2021, 106, 682–688. [CrossRef]

19. Madison, C.J.; Nelson, R.A.; Conlin, M.J.; Gundl, K.R.; Thompson, R.F.; Calverley, D.C. Thromboembolic risk in patients with lung cancer receiving systemic therapy. Br. J. Haematol. 2021, 194, 179–190. [CrossRef]

20. Moik, F.; Chan, W.-S.E.; Wiedemann, S.; Hoeller, C.; Tuchmann, F.; Aretin, M.-B.; Fuereeder, T.; Zochbauer-Muller, S.; Preusser, M.; Pabinger, I.; et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021, 137, 1669–1678. [CrossRef]

21. Roopkumar, J.; Swaidani, S.; Kim, A.S.; Thapa, B.; Gervaso, L.; Hobbs, B.P.; Wei, W.; Alban, T.J.; Funchain, P.; Kundu, S.; et al. Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med. 2021, 2, 423–434. [CrossRef]

22. Sussman, T.A.; Li, H.; Hobbs, B.; Funchain, P.; McCrae, K.R.; Khorana, A.A. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J. Immunother. Cancer 2021, 9, e001719. [CrossRef] [PubMed]

23. Moik, F.; Ay, C.; Horvath-Pubah, E.; Pabinger, I.; Mulder, F.I.; van Es, N.; Soerensen, H.T. Risk of Venous and Arterial Thromboembolic Events in Patients Receiving Targeted Anti-Cancer Therapy—A Nationwide Cohort Study. In Proceedings of the International Society on Thrombosis and Haemostasis Congress, Philadelphia, PA, USA, 17–21 July 2021.

24. Hu, Y.B.; Zhang, Q.; Li, H.J.; Michot, J.M.; Liu, H.B.; Zhan, P.; Lv, T.F.; Song, Y. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2017, 6, S8–S20. [CrossRef]

25. Nso, N.; Antwi-Amoabeng, D.; Beutler, B.D.; Ulanja, M.B.; Ghuman, J.; Hanfy, A.; Nimo-Boampong, J.; Atanga, S.; Doshi, R.; Enoru, S.; et al. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J. Cardiol. 2020, 12, 584–598. [CrossRef]

26. Solinas, C.; Saba, L.; Sganzarla, P.; Petrelli, F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thromb. Res. 2020, 196, 444–453. [CrossRef]

27. Agostinetto, E.; Eiger, D.; Lomberti, M.; Ceppi, M.; Biffone, M.; Ponde, N.; Plummer, C.; Awada, A.H.; Santoro, A.; Piacentini-Gebhart, M.; et al. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. Eur. J. Cancer 2021, 148, 76–91. [CrossRef]

28. Urvyler, P.; Earnshaw, I.; Bermudez, M.; Perucha, E.; Wu, W.; Ryan, S.; McDonald, L.; Karagiannis, S.N.; Taams, L.S.; Powell, N.; et al. Mechanisms of checkpoint inhibition-induced adverse events. Clin. Exp. Immunol. 2020, 200, 141–154. [CrossRef] [PubMed]

29. Cochain, C.; Chaudhari, S.M.; Koch, M.; Wiendl, H.; Eckstein, H.H.; Zernecke, A. Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS ONE 2014, 9, e93280. [CrossRef]

30. Bu, D.X.; Tarrio, M.; Maganto-Garcia, E.; Stavrakis, G.; Tajima, G.; Lederer, J.; Jarolim, P.; Freeman, G.J.; Sharp, A.H.; Lichtman, A.H. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1100–1107. [CrossRef] [PubMed]

31. Inno, A.; Chiampian, A.; Lanzoni, L.; Verze, M.; Molon, G.; Gori, S. Immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients. Front. Cardiovasc. Med. 2021, 8, 484. [CrossRef] [PubMed]

32. Del Prete, G.; De Carli, M.; Lammel, R.M.; D’Elleos, M.M.; Daniel, K.C.; Giusti, B.; Abbate, R.; Romagnani, S. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 1995, 86, 250–257. [CrossRef]

33. Horio, Y.; Takamatsu, K.; Tamanoi, D.; Sato, R.; Saruwatari, K.; Ikeda, T.; Nakane, S.; Nakajima, S.; Sae, F.; Ichiyasu, H.; et al. Trouseau’s syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient. Eur. J. Immunol. 2018, 48, 1764–1767. [CrossRef]

34. Bouitte, A.M.; McDonald, W.H.; Shyr, Y.; Yang, L.; Lin, P.C. Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS ONE 2011, 6, e22446. [CrossRef]

35. Sacchi, A.; Grassi, G.; Notari, S.; Gili, S.; Bordoni, V.; Tartaglia, E.; Casetti, R.; Cimini, E.; Mariotti, D.; Garotto, G.; et al. Expansion of Myeloid Derived Suppressor Cells Contributes to Platelet Activation by L-Arginine Deprivation during SARS-CoV-2 Infection. Cells 2021, 10, 2111. [CrossRef]

36. Alfaro, C.; Teijeira, A.; Onate, C.; Perez, G.; Samnpeed, M.F.; Andueza, M.P.; Alignani, D.; Labiano, S.; Azpilikueta, A.; Rodriguez-Paulete, A.; et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin. Cancer Res. 2016, 22, 3924–3936. [CrossRef] [PubMed]

37. Engelmann, B.; Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013, 13, 34–45. [CrossRef]

38. Petrelli, F.; Solinas, C. Reply to the letter to the editor ‘Reply to Solinas et al. venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review’ by Fere et al. Thromb. Res. 2021. [CrossRef]
39. Mandala, M.; Barni, S.; Floriani, I.; Isa, L.; Fornarini, G.; Marangolo, M.; Mosconi, S.; Corsi, D.; Rulli, E.; Frontini, L.; et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findings. *Eur. J. Cancer* 2009, 45, 65–73. [CrossRef]

40. Chiasakul, T.; Patell, R.; Maraveyas, A.; Carrier, M.; Zwicker, J.I. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. *J. Thromb. Haemost.* 2021, 19, 489–501. [CrossRef]

41. Carrier, M.; Khorana, A.A.; Zwicker, J.I.; Lyman, G.H.; Le Gal, G.; Lee, A.Y.; on behalf of the subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Venous thromboembolism in cancer clinical trials: Recommendation for standardized reporting and analysis. *J. Thromb. Haemost.* 2012, 10, 2599–2601. [CrossRef]

42. Li, H.; Sun, X.; Sun, D.; Zhao, J.; Xu, Z.; Zhao, P.; Ma, Z.; Zhang, Y. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. *Int. Immunopharmacol.* 2021, 98, 107818. [CrossRef]

43. Di Nisio, M.; van Es, N.; Carrier, M.; Wang, T.F.; Garcia, D.; Segers, A.; Weitz, J.; Buller, H.; Raskob, G. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. *J. Thromb. Haemost.* 2019, 17, 1866–1874. [CrossRef] [PubMed]

44. Carrier, M.; Wang, T.F. Direct oral anticoagulants and cancer-associated VTE: Good for all, or just some? *Blood* 2020, 136, 669–673. [CrossRef] [PubMed]

45. Lyman, G.H.; Carrier, M.; Ay, C.; Di Nisio, M.; Hicks, L.K.; Khorana, A.A.; Leavitt, A.D.; Lee, A.Y.Y.; Macbeth, F.; Morgan, R.L.; et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. *Blood Adv.* 2021, 5, 927–974. [CrossRef] [PubMed]

46. Key, N.S.; Khorana, A.A.; Kuderer, N.M.; Bohlke, K.; Lee, A.Y.Y.; Arcelus, J.I.; Wong, S.L.; Balaban, E.P.; Flowers, C.R.; Francis, C.W.; et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J. Clin. Oncol.* 2020, 38, 496–520. [CrossRef] [PubMed]

47. Carrier, M.; Abou-Nassar, K.; Mallick, R.; Tagalakis, V.; Shivakumar, S.; Schattner, A.; Kuruvilla, P.; Hill, D.; Spadafora, S.; Marquis, K.; et al. Apixaban to Prevent Venous Thromboembolism in Patients With Cancer. *N. Engl. J. Med.* 2019, 380, 710–719. [CrossRef]

48. Khorana, A.A.; Soff, G.A.; Kakkar, A.K.; Vadhvan-Raj, S.; Riess, H.; Wun, T.; Streiff, M.B.; Garcia, D.A.; Liebman, H.A.; Belani, C.P.; et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N. Engl. J. Med.* 2019, 380, 720–728. [CrossRef]

49. Cortellini, A.; Tucci, M.; Adamo, V.; Stucci, L.S.; Russo, A.; Tanda, E.T.; Spagnolo, F.; Rastelli, F.; Bisonni, R.; Santini, D.; et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. *J. Immunother. Cancer* 2020, 8, e01361. [CrossRef]

50. Ruf, W.; Graf, C. Coagulation signaling and cancer immunotherapy. *Thromb. Res.* 2020, 191, S106–S111. [CrossRef]

51. Graf, C.; Wilgenbus, P.; Pagel, S.; Pott, J.; Marinii, F.; Reyda, S.; Kitano, M.; Macher-Goppinger, S.; Weiler, H.; Ruf, W. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. *Sci. Immunol.* 2019, 4, eaaw8405. [CrossRef]

52. Johannet, P.; Sawyers, A.; Gulati, N.; Donnelly, D.; Kozlof, S.; Qian, Y.; Floristan, A.; Hernando, E.; Zhong, J.; Osman, I. Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. *J. Transl. Med.* 2021, 19, 1–7. [CrossRef]